New developments in medical mycology;Neue entwicklungen in der medizinischen mykologie

Hautarzt

Volumn 52, Issue 2, 2001, Pages 91-97

  Korting, H C ^a   Schaller, M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Amphotericin B; Aspartic proteinase; Candida dubliniensis; Onychomycosis; Oral candidosis; Terbinafine; Tinea pedis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ASPARTIC PROTEINASE; ITRACONAZOLE; TERBINAFINE;

CANDIDA DUBLINIENSIS; CANDIDIASIS; DERMATOMYCOSIS; ERYSIPELAS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MYCOLOGY; MYCOSIS; ONYCHOMYCOSIS; PATHOGENESIS; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; TINEA PEDIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASPARTIC ENDOPEPTIDASES; AXILLA; CANDIDA ALBICANS; CANDIDIASIS; CANDIDIASIS, CUTANEOUS; CANDIDIASIS, ORAL; CANDIDIASIS, VULVOVAGINAL; CASE-CONTROL STUDIES; CHILD; CLINICAL TRIALS; DERMATOMYCOSES; FEMALE; HUMANS; LIPOSOMES; MICROSCOPY, IMMUNOELECTRON; MULTICENTER STUDIES; MULTIVARIATE ANALYSIS; NAPHTHALENES; ONYCHOMYCOSIS; PRACTICE GUIDELINES; PROSPECTIVE STUDIES; RISK FACTORS; TINEA; TINEA PEDIS; TRICHOPHYTON;

EID: 0035135762     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001050051271     Document Type: Review

References (47)

1. Prevalence, morbidity and cost of dermatological diseases
2. Nicht gut zu Fuß: Jeder Dritte hat eine Haut-oder Zehennagelmykose
3. Erkenntnisse aus der "Footcheck" Fußforschung 97/98 in der Praxis umsetzen
4. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis
5. Trichophyton-rubrum-syndrom mit tinea axillaris als teilmanifestation
6. Cost-effectiveness of two new treatments for onychomycosis: An analysis of two comparative clinical trials
7. Nail changes in patients infected with human immunodeficiency virus. A prospective controlled study
8. Two feet-one hand syndrome: A retrospective multicenter survey
9. Effect of onychomycosis on quality of life
10. Risk factors for erysipelas of the leg (cellulitis): Case-controlled study
11. Cost-effectiveness analysis for onychomycosis therapy in Canada from government perspective
12. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis
13. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistence in clinical Candida albicans strains
14. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists' offices in Ontario, Canada - A multicenter survey of 2001 patients
15. Prevalence and epidemiology of toe-nail onychomycosis in diabetic subjects: A multicenter survey
16. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: A multicenter study
17. Inhibitors of aspartic proteases in human diseases: Molecular modeling comes of age
18. The role of Candida albicans secreted aspartic proteinase in the development of candidoses
19. Shift from persistent oral pseudomembranous to erythematous candidosis in a human immunodeficiency virus (HIV)-infected patient upon combination treatment with an HIV-protease inhibitor
20. HIV-protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: A 2-year study
21. Persistent oral candidosis by non-albicans Candida strains including Candida glabrata in a human immuno-deficiency virus-infected patient observed over a period of six years
22. Disruption of each of the secreted aspartyl proteinase genes SAP-1, SAP-2, and SAP-3 of Candida albicans attenuates virulence
23. The definition of Trichophyton rubrum syndrome
24. Dermatophytes on the feet of HIV-infected patients: Frequency, species distribution, localization and antimicrobial susceptibility
25. Liposomes in delivery of antifungals
26. Comparative efficacy and tolerability of econazole liposomal gel 1%, branded econazole conventional cream 1% and generic clotrimazole cream 1% in Tinea pedis
27. Results of German multicenter study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium
28. Is tinea unguium still widely incurable?
29. Effects of the Human Immundeficiency Virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients
30. Qualitätssicherung in der dermatologischen diagnostik
31. Cultural evidence for a bullous type of tinea pedis
32. Rapid PCR test for discriminating between Candida albicans and Candida dubliniensis isolates using primers derived from the pH-regulated pH-R1 and pH-R2 genes of C. albicans
33. Tinea pedis pathophysiology and treatment
34. Molecular epidemiology of Candida isolates from AIDS patients showing different fluconazole-resistence profiles
35. Quality of life of persons with onychomycosis
36. Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia in bone marrow transplantation
37. Management of onychomycoses
38. Mechanisms of adherence of Candida albicans to cultured human epidermal keratinocytes
39. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrrhexia of unknown origin in neutropenic patients
40. Prevalence of dermatophyte onychomycosis in the United Kingdom: Results of an omnibus survey
41. Emergence of fluconazole-resistent strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immuno-deficiency virus infection
42. In vivo expression and localization of Candida albicans secreted aspartyl proteinases during oral candidiasis in HIV-infected patients
43. Light and electron microscopic findings in a model of human cutaneous candidosis based on reconstructed human epidermis following the topical application of different econazole formulations
44. Onychomycosis is more than a cosmetic problem
45. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toe-nail
46. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
47. Chronic dermatophytosis syndrome due to Trichophyton rubrum